Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase NA 1Phase 4 1

Status

Completed 4

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Conditions

Breast Neoplasms 1484Neoplasms 1101Carcinoma, Non-Small-Cell Lung 918Prostatic Neoplasms 802Multiple Myeloma 586Colorectal Neoplasms 535Leukemia, Myeloid, Acute 505Lung Neoplasms 489Lymphoma 455Melanoma 454Neoplasm Metastasis 451Lymphoma, Non-Hodgkin 416Leukemia 409Leukemia, Lymphocytic, Chronic, B-Cell 366Ovarian Neoplasms 357Pancreatic Neoplasms 338Precursor Cell Lymphoblastic Leukemia-Lymphoma 334Recurrence 315Head and Neck Neoplasms 298Lymphoma, Follicular 297Myelodysplastic Syndromes 282Carcinoma, Renal Cell 272Glioblastoma 266Brain Neoplasms 265Hodgkin Disease 260Lymphoma, Large B-Cell, Diffuse 255Carcinoma, Hepatocellular 241Lymphoma, Mantle-Cell 219Squamous Cell Carcinoma of Head and Neck 214Stomach Neoplasms 210

Interventions

Inosine Monophosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Has results × Low Back Pain × Clear all
NCT03031938 2021-06-25

Protocol to Monitor the Neurological Development of Infants With Exposure in Utero From Birth to 15 Months in Tanezumab Clinical Studies

Pfizer

Phase 3 Completed
4 enrolled 78 charts

Cancer Pain, Osteoarthritis, Low Back Pain

NCT02367820 2021-06-22

SUMMIT-LTS

Nektar Therapeutics

Phase 3 Completed
638 enrolled 12 charts

Low Back Pain, Chronic Pain

NCT02871739 2019-02-08

A Trial Comparing Approaches to Shared Decision Making Skills Training for Clinicians

Massachusetts General Hospital

Phase NA Completed
23 enrolled 7 charts

Depression, Low Back Pain

NCT02519387 2016-07-20

Efficacy and Safety of Buprenorphine Transdermal Patch in Non-cancer Pain of Moderate Intensity

Mundipharma Pharmaceuticals Sdn. Bhd.

Phase 4 Completed
78 enrolled 9 charts

Arthritis, Rheumatoid, Osteoarthritis, Low Back Pain, Arthralgia, Myalgia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡